Moreover, cetuximab therapeutically blocks EGFR, and this might concurrently induce the activation of IGF-1R, which could activate EGFR-downstream Akt signaling, thus mediating cetuximab resistance in gastric cancer cells (Li et al., 2015). Here, AKT1 is linked to gastric cancer.